Overview

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

Status:
Not yet recruiting
Trial end date:
2023-04-29
Target enrollment:
Participant gender:
Summary
The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.
Phase:
Phase 2
Details
Lead Sponsor:
Imbria Pharmaceuticals, Inc.